Product menu

Picture of doctor speaking to patient

SHINGRIX: Recommendations from NACI and CIQ

Not an actual patient or doctor.

NACI Recommendation

Checkmark icon Checkmark icon

The National Advisory Committee on Immunization (NACI) recommends that SHINGRIX should be offered to adults 50 years of age and older (strong recommendation).1

According to NACI, a strong recommendation applies to most individuals and should be followed unless a clear and compelling rationale for an alternative approach is present.1

Refer to the NACI statement on the Public Health Agency website for further information.

© All rights reserved. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccine. Public Health Agency of Canada modified: 2018. Adapted and reproduced with permission from the Minister of Health, 2018.

CIQ Recommendation

Checkmark icon Checkmark icon

The Comité sur l’immunisation du Québec (CIQ) preferentially recommends SHINGRIX for:2

  • Adults 50 years of age and older.
  • Immunocompromised* adults 18 years of age and older.

Immunocompromised populations are heterogeneous, with their level of immune competence depending on many factors: disease severity and duration, clinical stability, complications and comorbidities, any potentially immunosuppressing treatment. Safety and immunogenicity data on SHINGRIX may not be available for all adults at increased risk of HZ. Consider patients on an individual basis.

* The PIQ includes the following as causes of significant immunosuppression:3

  • Congenital immune deficiency (e.g.,: DiGeorge syndrome, agammaglobulinemia, or hypogammaglobulinemia).
  • Leukemia, lymphoma, multiple myeloma, or non-hematologic cancer (immunosuppression caused by disease, chemotherapy, or radiation therapy).
  • Immunosuppressive agents (chemotherapy, radiotherapy, corticosteroids, biological agents).
  • Acquired immune deficiencies (e.g.,: HIV infection and AIDS).
90% Efficacy

See the SHINGRIX efficacy data in adults ≥50 years

Vaccine efficacy profile was studied in subjects ≥50 years old (ZOE-50) and subjects ≥70 years old (ZOE-70).4

Learn more
Patient icon

Meet the patients that are eligible to receive SHINGRIX

Nearly everyone ≥50 years old should be protected against shingles.1

Learn more
Vaccine icon

Dosing and administration

Discover more about administering the vaccine and discussing shingles and vaccination with your patients.

Learn more

References:

  1. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html. Accessed November 30, 2022.
  2. Reproduction of information from the PIQ, 7th ed. Zona-SU section. Available at: http://www.msss.gouv.qc.ca/professionnels/vaccination/piq-vaccins/zona-su-vaccin-sous-unitaire-contre-le-zona/. Accessed November 30, 2022.
    The original French version of this information was published in 2021 by the Department of Health and Social Services. The Dept. declines any responsibility for any damage, loss or injury that may result from this translation into English. In case of contradiction between the English and French versions of this information, the latter will prevail. The Government of Quebec is and remains the only copyright owner of the work in French. The English version has not been validated by the Ministry of Health and Social Services.
  3. Protocole d'immunisation du Québec (PIQ). Vaccinologie pratique Immunodépression. https://www.msss.gouv.qc.ca/professionnels/vaccination/piq-vaccinologie-pratique/immunodepression/. Accessed January 12, 2022.
  4. SHINGRIX Product Monograph. GlaxoSmithKline Inc., November 15, 2022.

Trademarks are owned by or licensed to the GSK group of companies.

©2022 GSK Group of Companies or its licensor.

10661 | 06/23